Head-to-head · WeighScore
Fitstry vs Gala Health
The verdict
Gala Health takes it — 82.9/100 to 61.2/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fitstry | Gala Health |
|---|---|---|
| WeighScore | 61.2/100 | 82.9/100 |
| Grade | C | B− |
| Scorecard rank | #300 | #17 |
| Semaglutide | $179/mo (annual plan, plus a separate fee, compounded) | Not disclosed |
| Tirzepatide | $269/mo (annual plan, compounded) | $179/mo (yearly subscription) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #300 · C
Strengths
- Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
- Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
- Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
- Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
- Full compounded lineup — weekly injection, daily oral tablet and microdosing options
Where it loses points
- Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
- Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Graded #17 · B−
Strengths
- Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
- Prices are published openly rather than quiz-gated, with all doses included at the one rate
- All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet — injection only
- Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.